• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Indivior Pharmaceuticals Inc.

    2/17/26 1:37:56 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INDV alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Indivior Pharmaceuticals, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    G4766E116

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    G4766E116


    1Names of Reporting Persons

    Fuller & Thaler Asset Management, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CALIFORNIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6,193,613.70
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    6,371,533.70
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,371,533.70
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.10 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Indivior Pharmaceuticals, Inc.
    (b)Address of issuer's principal executive offices:

    10710 MIDLOTHIAN TURNPIKE, SUITE 125, NORTH CHESTERFIELD, VA, 23235
    Item 2. 
    (a)Name of person filing:

    Fuller & Thaler Asset Management, Inc.
    (b)Address or principal business office or, if none, residence:

    411 Borel Avenue, Suite 300, San Mateo, CA 94402
    (c)Citizenship:

    California corporation
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    G4766E116
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    6,371,533.70
    (b)Percent of class:

    5.10%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    6,193,613.70

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    6,371,533.70

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Fuller & Thaler Asset Management, Inc. is deemed to be the beneficial owner of the number of securities reflected in Items 5-9 and 11 of page two (2) of this Schedule 13G pursuant tos eparate arrangements whereby it acts as investment adviser to certain persons. Each person for whom Fuller & Thaler Asset Management, Inc. acts as investment adviser has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Fuller & Thaler Asset Management, Inc.
     
    Signature:/s/ Hanna Zanoni
    Name/Title:Chief Compliance Officer
    Date:02/17/2026
    Get the next $INDV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INDV

    DatePrice TargetRatingAnalyst
    8/6/2025$27.00Buy
    H.C. Wainwright
    7/22/2025$20.00Buy
    Jefferies
    1/28/2025$16.00Buy
    Rodman & Renshaw
    7/23/2024$22.00Overweight
    Piper Sandler
    4/3/2024$37.00Buy
    Craig Hallum
    7/13/2023$35.00Outperform
    Northland Capital
    More analyst ratings

    $INDV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder

    Patients adherent to SUBLOCADE® for 12 months had 42% lower adjusted non-MOUD medical costs vs. those adherent to other forms of MOUDPatients adherent to SUBLOCADE had the lowest inpatient, emergency department, and detoxification utilization across all treatment groups RICHMOND, Va., March 11, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals (NASDAQ:INDV) today announced findings from a new real-world evidence, retrospective observational study published in Frontiers in Public Health showing that adherence to SUBLOCADE® (extended-release buprenorphine), a monthly injectable, is associated with meaningfully lower healthcare utilization and medical costs among commercially insured patient

    3/11/26 9:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results

    Generated Record Quarterly and Full-Year Total SUBLOCADE® Net Revenue of $252 Million and $856 MillionAchieved Quarterly and Full-Year GAAP Net Income of $102 Million and $210 Million; Non-GAAP Quarterly and Full-Year Net Income of $107 Million and $320 MillionDelivered Record Quarterly and Full-Year Adjusted EBITDA of $142 Million and $428 MillionEntered Phase II of the Indivior Action Agenda – Accelerate – on January 1, 2026Authorized New $400 Million Share Repurchase ProgramReaffirmed Full-Year 2026 Financial Guidance Announced on January 8, 2026Conference Call at 8:00 A.M. EST Today RICHMOND, Va., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today

    2/26/26 7:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior to Participate in Upcoming Investor Conferences

    RICHMOND, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced that it will participate in the following upcoming investor conferences: Barclays 28th Annual Global Healthcare Conference – Miami, FLJoe Ciaffoni, Chief Executive Officer, will host 1x1 / group meetings on Tuesday, March 10th. Joe Ciaffoni will also participate in a fireside chat on Tuesday, March 10th at 2:00 p.m. U.S. EST. Interested investors should contact their Barclays representative to schedule a meeting. The fireside chat will be publicly available and can be accessed using the following weblink: Barclays Webcast Link. 2026 Jefferies Biotech on the Beach Summit – Miami,

    2/24/26 7:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kingsley Stuart A bought $29,953 worth of shares (940 units at $31.86), increasing direct ownership by 20% to 5,582 units (SEC Form 4)

    4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)

    3/11/26 9:54:36 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ryan Barbara bought $1,009 worth of shares (31 units at $32.56), increasing direct ownership by 0.55% to 5,716 units (SEC Form 4)

    4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)

    3/11/26 8:12:31 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Accounting Officer Anderson Woodrow D converted options into 24,310 shares and covered exercise/tax liability with 10,965 shares, increasing direct ownership by 118% to 24,638 units (SEC Form 4)

    4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)

    3/5/26 4:00:48 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Indivior with a new price target

    H.C. Wainwright initiated coverage of Indivior with a rating of Buy and set a new price target of $27.00

    8/6/25 8:01:45 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on Indivior with a new price target

    Jefferies resumed coverage of Indivior with a rating of Buy and set a new price target of $20.00

    7/22/25 7:52:44 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Indivior with a new price target

    Rodman & Renshaw initiated coverage of Indivior with a rating of Buy and set a new price target of $16.00

    1/28/25 7:14:13 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kingsley Stuart A bought $29,953 worth of shares (940 units at $31.86), increasing direct ownership by 20% to 5,582 units (SEC Form 4)

    4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)

    3/11/26 9:54:36 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ryan Barbara bought $1,009 worth of shares (31 units at $32.56), increasing direct ownership by 0.55% to 5,716 units (SEC Form 4)

    4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)

    3/11/26 8:12:31 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ryan Barbara bought $27,429 worth of Ordinary Shares (775 units at $35.39), increasing direct ownership by 65% to 1,963 units (SEC Form 4)

    4 - INDIVIOR PLC (0001625297) (Issuer)

    1/7/26 1:51:48 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    SEC Filings

    View All

    SEC Form 10-K filed by Indivior Pharmaceuticals Inc.

    10-K - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)

    2/26/26 4:03:42 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Indivior Pharmaceuticals Inc.

    8-K - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)

    2/26/26 7:00:22 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Indivior Pharmaceuticals Inc.

    SCHEDULE 13G - Indivior Pharmaceuticals, Inc. (0001625297) (Subject)

    2/17/26 1:37:56 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Leadership Updates

    Live Leadership Updates

    View All

    CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 22, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space.  Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 22, 2025  S&P 500 Addition CRH CRH Mat

    12/5/25 5:49:00 PM ET
    $ASIX
    $BAH
    $BWA
    Major Chemicals
    Industrials
    Professional Services
    Consumer Discretionary

    Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs

    RICHMOND, Va., July 8, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Vanessa Procter as Executive Vice President of Corporate Affairs, effective July 7, 2025. Vanessa is a seasoned corporate affairs leader with extensive experience in the biopharmaceutical industry, and will be responsible for Corporate Communications, Government Affairs, Policy and Advocacy at Indivior. "We are excited to welcome Vanessa to the Indivior team," said Joe Ciaffoni, Chief Executive Officer. "Vanessa has an impressive track record of aligning teams to pr

    7/8/25 8:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior Appoints Tony Kingsley to the Board of Directors

    RICHMOND, Va., June 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Tony Kingsley to the Board of Directors as an Independent Non-Executive Director, effective July 1, 2025. Mr. Kingsley was appointed pursuant to Indivior's relationship agreement with affiliates of Oaktree Capital Management, L.P., who supported his appointment. Tony Kingsley is an accomplished biopharmaceutical executive with a distinguished track record of building and leading organizations across multiple scientific disciplines, therapeutic areas, and stages of

    6/24/25 4:12:00 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Financials

    Live finance-specific insights

    View All

    Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results

    Generated Record Quarterly and Full-Year Total SUBLOCADE® Net Revenue of $252 Million and $856 MillionAchieved Quarterly and Full-Year GAAP Net Income of $102 Million and $210 Million; Non-GAAP Quarterly and Full-Year Net Income of $107 Million and $320 MillionDelivered Record Quarterly and Full-Year Adjusted EBITDA of $142 Million and $428 MillionEntered Phase II of the Indivior Action Agenda – Accelerate – on January 1, 2026Authorized New $400 Million Share Repurchase ProgramReaffirmed Full-Year 2026 Financial Guidance Announced on January 8, 2026Conference Call at 8:00 A.M. EST Today RICHMOND, Va., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today

    2/26/26 7:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ

    RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, at 7:00 a.m. U.S. EST. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EST. Access to the Live Webcast Presentation: The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begins. Live webcast link: https://edge.media-server.com/mmc/p/f78ufsat Par

    1/28/26 7:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance

    Q3'25 Total Net Revenue of $314m, up 2% YOY; Q3'25 SUBLOCADE® Net Revenue of $219m, up 15% YOYAnnounces the Optimization of Rest of World (ROW) Business Discontinued the Sales and Marketing Support of OPVEE®Expect Annual Operating Expense Savings of at Least $150m in 2026On Track to Enter Phase II of the Indivior Action Agenda — Accelerate — January 1, 2026Conference Call Scheduled for Today at 8:00 A.M. EasternRICHMOND, Va., Oct. 30, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today reported its financial results for the third quarter ended September 30, 2025, and provided a business update.

    10/30/25 7:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Indivior PLC

    SC 13G - INDIVIOR PLC (0001625297) (Subject)

    11/15/24 6:03:54 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Indivior PLC

    SC 13G/A - INDIVIOR PLC (0001625297) (Subject)

    11/14/24 5:00:25 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Indivior PLC

    SC 13D/A - INDIVIOR PLC (0001625297) (Subject)

    11/7/24 8:23:16 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care